Skip to main content
main-content

Oncology news

20-03-2017 | Oncology | Highlight | Article

Editor's pick

Maternal, fetal outcomes of pregnancy in cancer in focus

Two independent studies shed light on the effects of pregnancy during cancer, one finding that pregnancy does not adversely affect the survival of women with breast cancer and the other showing an association between maternal cancer and an increased risk for stillbirth and neonatal mortality.

Source:

JAMA Oncol 2017; Advance online publication, J Clin Oncol 2017; Advance online publication

24-03-2017 | Oncology | News | Article

Intestinal microbiota linked to reduced risk for post-HSCT relapse

Researchers have found an association between increased abundance of a bacterial group primarily comprising Eubacterium limosum in the intestinal microbiota and a reduced risk for relapse after undergoing allogeneic hematopoietic stem cell transplantation.

Source:

J Clin Oncol 2017; Advance online publication

24-03-2017 | Breast cancer | News | Article

News in brief

Triple-positive breast cancer patients with diabetes benefit from metformin

Researchers recommend the use of the antidiabetic agent metformin for the subset of women with human epidermal growth factor receptor-positive and hormone receptor-positive breast cancer who also have diabetes.

23-03-2017 | Lymphoma | News | Article

Excessive toxicity halts idelalisib, lenalidomide plus rituximab lymphoma trials

Two phase 1 trials investigating the safety and efficacy of combined idelalisib, lenalidomide, and rituximab in patients with relapsed and refractory follicular and mantle cell lymphoma have been stopped early due to excessive toxicity.

Source:

Lancet Haematol 2017; Advance online publication

22-03-2017 | Prostate cancer | News | Article

News in brief

No increase in prostate cancer risk with testosterone replacement

Testosterone replacement therapy is not associated with an increase in total prostate cancer risk, and may even decrease the risk for aggressive disease.

Localised Prostate Cancer Treatment-Related Side Effects, QoL Characterised

Patient experiences in the first 2–3 years after localised prostate cancer treatment differ with treatment modality

Read the full story on ESMO's oncologyPRO educational website (for registered ESMO members).

approvalsWatch: Oncology

ESMO 2016 coverage

medwireNews@ESMO2016

medwireNews brings you news and conference reports from the ESMO 2016 Congress, held in Copenhagen, Denmark.

Click through to read the full reports of the latest research.

Twitter Icon Follow medwireNews

Click here
image credits